Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 984 participants.
Also called NCT07730840
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 984 participants
- Registry
-
NCT07730840
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07730840. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-15 (anticipated); primary completion 2029-09-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke
- Condition
- Ischemic Stroke
- Condition
- Transient Ischemic Attack
- Intervention (Drug)
- Zastaprazan
- Intervention (Drug)
- Placebo
- Lead sponsor
- Asan Medical Center
- Collaborator
- Jeil Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07730840- Content hash
8b48e0433e417948607a7d58da7621fe1ca5ac3c430b82cde1e15be85a1bfd2e